USPTO serial 87937170
AFFIMER XT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- IN, SUNG HYUN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AFFIMER XT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
Alexandra MacKay STITES & HARBISON, PLLC401 COMMERCE STREETSUITE 800NASHVILLE, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Reagents for use in veterinary and medical diagnostic tests except tests in the field of immunohematology and transfusion medicine; reagents for use in medical and veterinary research except tests in the field of immunohematology and transfusion medicine; diagnostic reagents for use in medical and veterinary screening except tests in the field of immunohematology and transfusion medicine; diagnostic reagents for medical and veterinary diagnostic purposes for use in assays of biological samples, particularly blood except tests in the field of immunohematology and transfusion medicine; diagnostic reagents for medical and veterinary diagnostic purposes for use in assays of samples, particularly blood except tests in the field of immunohematology and transfusion medicine; diagnostic preparations for medical and veterinary diagnostic purposes for use in relation to food intolerance testing; pharmaceutical substances based on affinity reagents equivalent to antibodies, and products comprising them, all for use in medical and/or veterinary screening except tests in the field of immunohematology and transfusion medicine; pharmaceutical preparations in the nature of antigens for medical diagnostic use and veterinary diagnostic use and/or pharmaceutical purposes for the detection of cancer, inflammatory diseases, food allergies, infections, autoimmune disorders and for immunity testing but not immunohemotology and transfusion medicine; diagnostic and/or pharmaceutical preparations containing antigens except preparations in the field of immunohematology and transfusion medicine, for use in medical and veterinary treatment in the nature of anti-infectives, cancer immunotherapies, anti-inflammatory diseases, and genetic conditions; pharmaceutical preparation in the nature of substrates impregnated with or carrying antigens for medical diagnostic use and veterinary diagnostic use and pharmaceutical purposes other than immunohematology and transfusion medicine for the detection of cancers, inflammatory diseases, food allergies, infections, autoimmune disorders and for immunity testing; affinity reagents, namely, protein binding agents equivalent to antibodies for medical diagnostic use and veterinary diagnostic use and/or pharmaceutical purposes for the detection of cancers, inflammatory diseases, food allergies, infections, autoimmune disorders and for immunity testing but not immunohematology and transfusion medicine; pharmaceutical or diagnostic preparations containing affinity reagents, namely, protein binding agents equivalent to antibodies except in connection with immunohematology or transfusion medicine for medical diagnostic use and veterinary diagnostic use in the nature of anti-infectives, cancer immunotherapies, anti-inflammatory diseases and genetic conditions; pharmaceutical preparations in the nature of substrates impregnated with or carrying affinity reagents, namely, protein binding agents equivalent to antibodies for medical diagnostic use and veterinary diagnostic use in the nature of anti-infectives, cancer immunotherapies, anti-inflammatory diseases and genetic conditions; wound dressings; medical plasters; antiseptic wipes; diagnostic reagents for medical use except in connection with immunohematology and transfusion medicine containing any of the aforesaid products; food intolerance test kits comprising diagnostic test patches for application to the skin for determining allergies; reagents, namely, protein binding agents for use in scientific research; reagents, namely, protein binding agents for use in scientific screening; genetic testing kits comprised of reagents for medical purposes; genetic testing kits comprised of reagents for medical purposes for animals; genetic testing kits comprised of reagents for medical purposes; genetic testing kits comprised of reagents for medical purposes for animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 5, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 4, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 4, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 2, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 2, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 2, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 27, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 25, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 25, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 25, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 3, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 1, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 1, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 1, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 2, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 18, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 29, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 6, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 6, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 6, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 6, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 6, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 18, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jun 3, 2019 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| May 31, 2019 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| May 23, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 15, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 15, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 15, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 8, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Apr 10, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 10, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 10, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 20, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 20, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 20, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 24, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 29, 2018 | NWAP | NEW APPLICATION ENTERED | — |